Contineum Therapeutics (CTNM) Financials

Contineum Therapeutics logo
$9.55 -0.12 (-1.24%)
Closing price 04:00 PM Eastern
Extended Trading
$9.55 0.00 (0.00%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Annual Income Statements for Contineum Therapeutics

Annual Income Statements for Contineum Therapeutics

This table shows Contineum Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2023 2024 2025
Period end date 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders
3.15 -42 -60
Consolidated Net Income / (Loss)
23 -42 -60
Net Income / (Loss) Continuing Operations
23 -42 -60
Total Pre-Tax Income
23 -42 -60
Total Operating Income
16 -51 -68
Total Gross Profit
50 0.00 0.00
Total Revenue
50 0.00 0.00
Total Cost of Revenue
0.00 0.00 0.00
Total Operating Expenses
34 51 68
Selling, General & Admin Expense
6.32 12 17
Research & Development Expense
28 38 52
Total Other Income / (Expense), net
7.09 8.64 8.08
Interest & Investment Income
4.61 8.91 8.25
Other Income / (Expense), net
2.70 -0.27 -0.17
Basic Earnings per Share
$1.36 ($2.18) ($2.17)
Weighted Average Basic Shares Outstanding
2.31M 19.35M 27.70M
Diluted Earnings per Share
$0.08 ($2.18) ($2.17)
Weighted Average Diluted Shares Outstanding
3.40M 19.35M 27.70M
Weighted Average Basic & Diluted Shares Outstanding
- 25.87M 37.34M

Quarterly Income Statements for Contineum Therapeutics

This table shows Contineum Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Total Costs & Expenses
- - - - - - 15 - - - 21
Net Income / (Loss) Attributable to Common Shareholders
-8.42 -9.01 -10 -15 -16 -16 -13 -15 -14 -15 -19
Consolidated Net Income / (Loss)
-8.42 -9.01 -10 -15 -16 -16 -13 -15 -14 -15 -19
Net Income / (Loss) Continuing Operations
-8.42 -9.01 -10 -15 -16 -16 -13 -15 -14 -15 -19
Total Pre-Tax Income
-8.42 -9.01 -10 -15 -16 -16 -13 -15 -14 -15 -19
Total Operating Income
-9.93 -11 -13 -17 -18 -18 -15 -17 -17 -17 -21
Total Gross Profit
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Revenue
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Cost of Revenue
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Operating Expenses
9.93 11 13 17 18 18 15 17 17 17 21
Selling, General & Admin Expense
2.15 3.04 3.25 4.03 4.40 3.84 3.94 4.36 5.26 4.73 4.98
Research & Development Expense
7.78 7.90 9.73 13 14 14 11 13 12 13 16
Total Other Income / (Expense), net
1.51 1.94 2.71 2.48 2.12 1.86 2.14 1.69 2.45 2.27 2.27
Interest & Investment Income
1.64 2.00 2.74 2.53 2.25 2.03 1.96 2.01 2.51 2.34 2.36
Other Income / (Expense), net
-0.12 -0.07 -0.03 -0.05 -0.13 -0.17 0.18 -0.05 -0.06 -0.07 -0.09
Basic Earnings per Share
($3.55) ($0.39) ($0.40) $2.16 ($0.62) ($0.62) ($0.45) ($0.48) ($0.39) ($0.40) ($0.49)
Weighted Average Basic Shares Outstanding
2.37M 23.36M 25.73M 19.35M 25.87M 25.90M 28.12M 27.70M 37.34M 37.47M 38.39M
Diluted Earnings per Share
- - - - ($0.62) ($0.62) ($0.45) - ($0.39) ($0.40) ($0.49)
Weighted Average Diluted Shares Outstanding
25.72M 18.99M 25.78M 19.35M 25.87M 25.90M 28.12M 27.70M 37.34M 37.47M 38.39M
Weighted Average Basic & Diluted Shares Outstanding
25.72M 18.99M 25.78M 25.87M 25.87M 28.04M 23.10M 37.34M 37.39M 37.62M 39.27M

Annual Cash Flow Statements for Contineum Therapeutics

This table details how cash moves in and out of Contineum Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2023 2024 2025
Period end date 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents
9.96 6.42 54
Net Cash From Operating Activities
19 -33 -55
Net Cash From Continuing Operating Activities
19 -33 -55
Net Income / (Loss) Continuing Operations
23 -42 -60
Consolidated Net Income / (Loss)
23 -42 -60
Depreciation Expense
0.20 0.26 0.32
Amortization Expense
-2.87 -3.94 -0.79
Non-Cash Adjustments To Reconcile Net Income
1.87 7.83 9.91
Changes in Operating Assets and Liabilities, net
-2.56 5.27 -4.78
Net Cash From Investing Activities
-66 -70 -3.71
Net Cash From Continuing Investing Activities
-66 -70 -3.71
Purchase of Property, Plant & Equipment
-0.41 -0.51 -0.23
Purchase of Investments
-142 -226 -163
Sale of Property, Plant & Equipment
0.00 0.02 0.00
Sale and/or Maturity of Investments
77 157 159
Net Cash From Financing Activities
56 109 113
Net Cash From Continuing Financing Activities
56 109 113
Repurchase of Common Equity
-0.37 0.00 -0.26
Issuance of Common Equity
0.00 109 113
Other Financing Activities, net
0.16 0.41 0.22

Quarterly Cash Flow Statements for Contineum Therapeutics

This table details how cash moves in and out of Contineum Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Change in Cash & Equivalents
0.74 61 -36 -19 0.53 -1.69 22 33 -55 -5.45 60
Net Cash From Operating Activities
-7.98 -8.50 -6.17 -10 -14 -16 -12 -13 -16 -12 -11
Net Cash From Continuing Operating Activities
-7.98 -8.50 -6.17 -10 -14 -16 -12 -13 -16 -12 -11
Net Income / (Loss) Continuing Operations
-8.42 -9.01 -10 -15 -16 -16 -13 -15 -14 -15 -19
Consolidated Net Income / (Loss)
-8.42 -9.01 -10 -15 -16 -16 -13 -15 -14 -15 -19
Depreciation Expense
0.06 0.06 0.06 0.08 0.08 0.08 0.08 0.09 0.08 0.13 0.08
Amortization Expense
-1.02 -1.07 -0.78 - -0.29 -0.41 0.00 -0.10 -0.40 -0.85 0.67
Non-Cash Adjustments To Reconcile Net Income
1.14 1.74 2.51 1.34 2.61 2.39 2.55 2.37 3.15 3.98 4.95
Changes in Operating Assets and Liabilities, net
0.26 -0.22 2.31 2.95 -0.83 -1.68 -2.04 -0.24 -4.65 0.39 1.94
Net Cash From Investing Activities
8.73 -39 -30 -9.39 15 14 15 -47 -39 4.85 51
Net Cash From Continuing Investing Activities
8.73 -39 -30 -9.39 15 14 15 -47 -39 4.85 51
Purchase of Investments
-31 -69 -72 -54 -34 -25 -19 -85 -97 -46 -16
Sale and/or Maturity of Investments
40 30 42 45 49 39 34 37 58 51 67
Net Cash From Financing Activities
-0.02 108 0.01 0.64 0.02 0.09 19 93 0.13 1.20 21
Net Cash From Continuing Financing Activities
-0.02 108 0.01 0.64 0.02 0.09 19 93 0.13 1.20 21
Repurchase of Common Equity
-0.14 0.14 - - 0.00 -0.18 -0.08 - -0.07 -0.05 0.06
Issuance of Common Equity
- - - 0.39 - - 19 93 - - 19
Other Financing Activities, net
0.12 0.01 0.01 0.26 0.02 - 0.17 0.02 0.20 0.47 1.10

Annual Balance Sheets for Contineum Therapeutics

This table presents Contineum Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2023 2024 2025
Period end date 12/31/2023 12/31/2024 12/31/2025
Total Assets
130 213 277
Total Current Assets
128 206 268
Cash & Equivalents
16 22 76
Short-Term Investments
110 183 187
Prepaid Expenses
2.52 1.63 5.02
Plant, Property, & Equipment, net
0.68 0.99 0.83
Total Noncurrent Assets
2.00 5.47 7.90
Other Noncurrent Operating Assets
2.00 5.47 7.90
Total Liabilities & Shareholders' Equity
130 213 277
Total Liabilities
5.70 15 16
Total Current Liabilities
5.48 9.97 9.74
Accounts Payable
0.64 1.81 1.02
Accrued Expenses
4.39 6.71 6.39
Other Current Liabilities
0.46 1.45 2.34
Total Noncurrent Liabilities
0.22 4.81 5.91
Other Noncurrent Operating Liabilities
0.22 4.81 5.91
Commitments & Contingencies
0.00 0.00 0.00
Total Equity & Noncontrolling Interests
-68 198 261
Total Preferred & Common Equity
-68 198 261
Preferred Stock
0.00 0.00 0.00
Total Common Equity
-68 198 261
Common Stock
7.10 315 438
Retained Earnings
-75 -117 -177
Accumulated Other Comprehensive Income / (Loss)
0.11 0.07 0.26

Quarterly Balance Sheets for Contineum Therapeutics

This table presents Contineum Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026 9/30/2026
Total Assets
124 221 216 198 183 191 261 250 257
Total Current Assets
120 220 215 192 177 185 253 243 250
Cash & Equivalents
16 77 41 22 21 43 20 15 75
Short-Term Investments
102 141 173 168 155 140 226 222 169
Prepaid Expenses
1.80 1.67 1.23 1.42 1.36 2.52 6.64 6.03 5.26
Plant, Property, & Equipment, net
0.76 0.80 0.89 0.89 0.86 0.88 1.06 0.93 0.85
Total Noncurrent Assets
3.10 0.23 0.00 5.24 5.19 5.04 7.33 6.86 6.40
Other Noncurrent Operating Assets
3.10 0.23 0.00 5.24 5.19 5.04 7.33 6.86 6.40
Total Liabilities & Shareholders' Equity
124 221 216 198 183 191 261 250 257
Total Liabilities
6.57 3.85 5.81 13 11 10 11 11 12
Total Current Liabilities
6.23 3.74 5.81 8.95 7.21 6.36 6.66 6.53 8.03
Accounts Payable
0.57 0.73 1.40 3.65 2.00 0.79 1.50 0.51 0.64
Accrued Expenses
5.19 2.52 3.80 3.85 3.75 4.10 2.86 3.63 4.66
Other Current Liabilities
0.47 0.48 0.61 1.46 1.47 1.48 2.30 2.39 2.72
Total Noncurrent Liabilities
0.34 0.11 0.00 4.55 4.28 4.02 4.65 4.18 3.54
Other Noncurrent Operating Liabilities
0.34 0.11 0.00 4.55 4.28 4.02 4.65 4.18 3.54
Commitments & Contingencies
- - - 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
-76 218 210 185 171 180 250 240 245
Total Preferred & Common Equity
-76 218 210 185 171 180 250 240 245
Preferred Stock
- 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
-76 218 210 185 171 180 250 240 245
Common Stock
7.99 310 313 318 321 342 442 447 473
Retained Earnings
-84 -93 -103 -133 -149 -162 -192 -207 -226
Accumulated Other Comprehensive Income / (Loss)
-0.06 -0.13 0.56 0.17 0.15 0.27 -0.25 -0.57 -1.51

Annual Metrics And Ratios for Contineum Therapeutics

This table displays calculated financial ratios and metrics derived from Contineum Therapeutics' official financial filings.

Metric 2023 2024 2025
Period end date 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding
0.00 - 23,099,173.00
DEI Adjusted Shares Outstanding
0.00 - 23,099,173.00
DEI Earnings Per Adjusted Shares Outstanding
0.00 - -2.60
Growth Metrics
- - -
Revenue Growth
0.00% -100.00% 0.00%
EBITDA Growth
0.00% -416.30% -25.25%
EBIT Growth
0.00% -372.55% -33.35%
NOPAT Growth
0.00% -325.98% -33.73%
Net Income Growth
0.00% -285.99% -41.93%
EPS Growth
0.00% -2,825.00% 0.46%
Operating Cash Flow Growth
0.00% -269.75% -68.40%
Free Cash Flow Firm Growth
0.00% 0.00% -78.10%
Invested Capital Growth
0.00% -1,222.92% 71.51%
Revenue Q/Q Growth
0.00% 0.00% 0.00%
EBITDA Q/Q Growth
0.00% 0.00% -4.63%
EBIT Q/Q Growth
0.00% 0.00% -0.11%
NOPAT Q/Q Growth
0.00% 0.00% -0.10%
Net Income Q/Q Growth
0.00% 0.00% -1.00%
EPS Q/Q Growth
0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth
0.00% 0.00% -5.41%
Free Cash Flow Firm Q/Q Growth
0.00% 0.00% -6.26%
Invested Capital Q/Q Growth
0.00% -81.75% 1.55%
Profitability Metrics
- - -
Gross Margin
100.00% 0.00% 0.00%
EBITDA Margin
32.19% 0.00% 0.00%
Operating Margin
32.15% 0.00% 0.00%
EBIT Margin
37.54% 0.00% 0.00%
Profit (Net Income) Margin
45.44% 0.00% 0.00%
Tax Burden Percent
98.06% 100.00% 100.00%
Interest Burden Percent
123.43% 82.59% 87.91%
Effective Tax Rate
1.94% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00%
Return on Equity (ROE)
18.22% -26.19% -26.13%
Cash Return on Invested Capital (CROIC)
0.00% 0.00% 0.00%
Operating Return on Assets (OROA)
14.40% 0.00% 0.00%
Return on Assets (ROA)
17.43% 0.00% 0.00%
Return on Common Equity (ROCE)
-9.93% -10.56% -26.13%
Return on Equity Simple (ROE_SIMPLE)
-33.44% -21.34% 0.00%
Net Operating Profit after Tax (NOPAT)
16 -36 -48
NOPAT Margin
31.53% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)
5.56% -4.02% -5.28%
Return On Investment Capital (ROIC_SIMPLE)
-23.21% -17.99% -18.25%
Cost of Revenue to Revenue
0.00% 0.00% 0.00%
SG&A Expenses to Revenue
12.64% 0.00% 0.00%
R&D to Revenue
55.21% 0.00% 0.00%
Operating Expenses to Revenue
67.85% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)
19 -51 -68
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
16 -51 -69
Valuation Ratios
- - -
Price to Book Value (P/BV)
0.00 1.91 1.01
Price to Tangible Book Value (P/TBV)
0.00 1.91 1.01
Price to Revenue (P/Rev)
2.20 0.00 0.00
Price to Earnings (P/E)
34.97 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00%
Earnings Yield
2.86% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)
3.55 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)
11.02 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
9.45 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
11.25 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
9.17 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00
Leverage & Solvency
- - -
Debt to Equity
0.00 0.00 0.00
Long-Term Debt to Equity
0.00 0.00 0.00
Financial Leverage
-1.00 -1.02 -1.02
Leverage Ratio
1.05 1.06 1.07
Compound Leverage Factor
1.29 0.88 0.94
Debt to Total Capital
0.00% 0.00% 0.00%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
0.00% 0.00% 0.00%
Preferred Equity to Total Capital
0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
154.49% 0.00% 0.00%
Common Equity to Total Capital
-54.49% 100.00% 100.00%
Debt to EBITDA
0.00 0.00 0.00
Net Debt to EBITDA
0.00 0.00 0.00
Long-Term Debt to EBITDA
0.00 0.00 0.00
Debt to NOPAT
0.00 0.00 0.00
Net Debt to NOPAT
0.00 0.00 0.00
Long-Term Debt to NOPAT
0.00 0.00 0.00
Altman Z-Score
12.75 14.87 9.53
Noncontrolling Interest Sharing Ratio
154.49% 59.68% 0.00%
Liquidity Ratios
- - -
Current Ratio
23.29 20.69 27.50
Quick Ratio
22.83 20.53 26.98
Cash Flow Metrics
- - -
Free Cash Flow to Firm (FCFF)
0.00 -29 -52
Operating Cash Flow to CapEx
4,673.67% -6,648.79% -23,944.59%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 0.00
Operating Cash Flow to Interest Expense
93.02 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
91.03 0.00 0.00
Efficiency Ratios
- - -
Asset Turnover
0.38 0.00 0.00
Accounts Receivable Turnover
0.00 0.00 0.00
Inventory Turnover
0.00 0.00 0.00
Fixed Asset Turnover
73.75 0.00 0.00
Accounts Payable Turnover
0.00 0.00 0.00
Days Sales Outstanding (DSO)
0.00 0.00 0.00
Days Inventory Outstanding (DIO)
0.00 0.00 0.00
Days Payable Outstanding (DPO)
0.00 0.00 0.00
Cash Conversion Cycle (CCC)
0.00 0.00 0.00
Capital & Investment Metrics
- - -
Invested Capital
-0.51 -6.69 -1.91
Invested Capital Turnover
-98.81 0.00 0.00
Increase / (Decrease) in Invested Capital
0.00 -6.19 4.79
Enterprise Value (EV)
177 173 1.13
Market Capitalization
110 378 264
Book Value per Share
($29.42) $7.68 $11.30
Tangible Book Value per Share
($29.42) $7.68 $11.30
Total Capital
125 198 261
Total Debt
0.00 0.00 0.00
Total Long-Term Debt
0.00 0.00 0.00
Net Debt
-125 -205 -263
Capital Expenditures (CapEx)
0.41 0.49 0.23
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-2.97 -8.35 -4.72
Debt-free Net Working Capital (DFNWC)
122 196 258
Net Working Capital (NWC)
122 196 258
Net Nonoperating Expense (NNE)
-6.96 6.63 12
Net Nonoperating Obligations (NNO)
-125 -205 -263
Total Depreciation and Amortization (D&A)
-2.68 0.26 -0.47
Debt-free, Cash-free Net Working Capital to Revenue
-5.94% 0.00% 0.00%
Debt-free Net Working Capital to Revenue
244.44% 0.00% 0.00%
Net Working Capital to Revenue
244.44% 0.00% 0.00%
Earnings Adjustments
- - -
Adjusted Basic Earnings per Share
$0.00 ($2.18) ($2.17)
Adjusted Weighted Average Basic Shares Outstanding
0.00 19.35M 27.70M
Adjusted Diluted Earnings per Share
$0.00 ($2.18) ($2.17)
Adjusted Weighted Average Diluted Shares Outstanding
0.00 19.35M 27.70M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
0.00 25.87M 37.34M
Normalized Net Operating Profit after Tax (NOPAT)
16 -36 -48
Normalized NOPAT Margin
31.53% 0.00% 0.00%
Pre Tax Income Margin
46.34% 0.00% 0.00%
Debt Service Ratios
- - -
EBIT to Interest Expense
90.25 0.00 0.00
NOPAT to Interest Expense
75.79 0.00 0.00
EBIT Less CapEx to Interest Expense
88.26 0.00 0.00
NOPAT Less CapEx to Interest Expense
73.80 0.00 0.00
Payout Ratios
- - -
Dividend Payout Ratio
0.00% 0.00% 0.00%
Augmented Payout Ratio
1.63% 0.00% -0.43%

Quarterly Metrics And Ratios for Contineum Therapeutics

This table displays calculated financial ratios and metrics derived from Contineum Therapeutics' official financial filings.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
DEI Shares Outstanding
0.00 25,723,276.00 18,994,104.00 - 25,871,549.00 25,871,549.00 28,041,895.00 23,099,173.00 37,336,036.00 37,386,377.00 37,621,132.00
DEI Adjusted Shares Outstanding
0.00 25,723,276.00 18,994,104.00 - 25,871,549.00 25,871,549.00 28,041,895.00 23,099,173.00 37,336,036.00 37,386,377.00 37,621,132.00
DEI Earnings Per Adjusted Shares Outstanding
0.00 -0.35 -0.54 - -0.62 -0.62 -0.46 -0.66 -0.39 -0.41 -0.50
Growth Metrics
- - - - - - - - - - -
Revenue Growth
0.00% -100.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth
-108.03% -128.75% -43.92% -56.38% -67.47% -53.07% -6.81% 4.97% 6.36% 1.00% -38.51%
EBIT Growth
-95.85% -126.38% -60.49% -75.84% -81.44% -64.11% -13.38% -0.43% 7.01% 3.17% -42.78%
NOPAT Growth
-94.13% -120.02% -60.79% -76.17% -82.38% -63.58% -15.09% -0.40% 6.66% 2.65% -40.41%
Net Income Growth
-74.48% -121.68% -64.25% -87.48% -89.97% -78.04% -24.59% -4.06% 9.59% 5.52% -46.16%
EPS Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 37.10% 35.48% -8.89%
Operating Cash Flow Growth
-52.08% -120.90% -14.73% 4.69% -80.71% -84.27% -97.71% -27.84% -12.86% 26.56% 9.32%
Free Cash Flow Firm Growth
0.00% 0.00% 0.00% 0.00% -26.78% -47.25% -125.95% -191.90% -180.85% -102.38% -43.85%
Invested Capital Growth
0.00% 0.00% 0.00% -1,222.92% -548.69% -256.00% 47.41% 71.51% 162.49% 175.94% 148.22%
Revenue Q/Q Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth
-1.22% -9.11% -14.23% -56.78% -2.02% 0.27% 20.29% -17.18% -0.52% -5.44% -11.52%
EBIT Q/Q Growth
-3.43% -9.52% -18.15% -31.40% -6.72% 0.94% 18.37% -16.39% 1.19% -3.15% -20.36%
NOPAT Q/Q Growth
-2.63% -10.21% -18.55% -31.39% -6.24% 1.15% 16.59% -14.62% 1.23% -3.10% -20.30%
Net Income Q/Q Growth
-8.34% -7.03% -13.96% -41.86% -9.78% -0.31% 20.25% -18.48% 4.62% -4.83% -23.38%
EPS Q/Q Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -2.56% -22.50%
Operating Cash Flow Q/Q Growth
25.50% -6.57% 27.42% -65.38% -41.27% -8.67% 22.12% -6.93% -24.72% 29.29% 3.83%
Free Cash Flow Firm Q/Q Growth
0.00% -7.88% 17.08% -6.40% -33.20% -25.31% -27.23% -37.46% -28.15% 9.70% 9.56%
Invested Capital Q/Q Growth
-81.03% -25.55% -220.26% -81.75% 11.23% 31.10% 52.69% 1.55% 294.70% -16.27% -69.96%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent
100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent
83.73% 81.83% 78.93% 85.22% 87.66% 88.77% 86.73% 88.29% 85.23% 86.61% 88.78%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)
16.35% -14.46% -16.87% -26.19% -33.03% -29.24% -30.40% -26.13% -26.88% -28.01% -29.80%
Cash Return on Invested Capital (CROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -1,520.39% -1,726.22% -5,734.49%
Operating Return on Assets (OROA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)
-10.57% -14.46% -16.87% -10.56% -11.95% -29.24% -30.40% -26.13% -26.88% -28.01% -29.80%
Return on Equity Simple (ROE_SIMPLE)
-25.29% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
-6.95 -7.66 -9.08 -12 -13 -13 -10 -12 -12 -12 -15
NOPAT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)
-2.49% -1.23% -1.11% -1.60% -2.15% -1.78% -1.18% -1.36% -1.20% -1.43% -1.88%
Return On Investment Capital (ROIC_SIMPLE)
9.19% -3.52% -4.32% -6.02% -6.86% -7.31% -5.79% -4.59% -4.73% -5.09% -5.98%
Cost of Revenue to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)
-10 -11 -13 -17 -18 -18 -15 -17 -17 -17 -21
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-11 -12 -14 -17 -18 -18 -15 -17 -17 -18 -20
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
0.00 2.08 1.73 1.91 0.98 0.60 1.83 1.01 1.95 2.56 2.06
Price to Tangible Book Value (P/TBV)
0.00 2.08 1.73 1.91 0.98 0.60 1.83 1.01 1.95 2.56 2.06
Price to Revenue (P/Rev)
2.20 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 64.98 121.01 278.79
Enterprise Value to Revenue (EV/Rev)
3.69 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)
17.81 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
13.33 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
16.40 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
11.12 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage
-1.01 -1.01 -1.02 -1.02 -1.02 -1.01 -1.01 -1.02 -1.01 -1.00 -1.00
Leverage Ratio
1.06 1.02 1.03 1.06 1.07 1.04 1.04 1.07 1.06 1.05 1.05
Compound Leverage Factor
0.88 0.83 0.81 0.91 0.93 0.92 0.90 0.94 0.90 0.91 0.93
Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
164.65% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
-64.65% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score
10.33 70.98 37.87 15.40 7.89 5.00 18.73 10.14 25.76 34.08 25.81
Noncontrolling Interest Sharing Ratio
164.65% 0.00% 0.00% 59.68% 63.83% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
19.20 58.92 37.06 20.69 21.47 24.51 29.07 27.50 38.00 37.17 31.11
Quick Ratio
18.91 58.48 36.84 20.53 21.31 24.33 28.68 26.98 37.00 36.25 30.45
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-6.04 -6.51 -5.40 -5.74 -7.65 -9.59 -12 -17 -21 -19 -18
Operating Cash Flow to CapEx
-5,425.17% -7,142.02% -7,523.17% -6,145.78% -30,663.83% -35,593.18% -12,445.92% -31,052.38% -5,213.46% -191,683.33% 0.00%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.40 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
66.14 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
-0.92 -1.15 -3.68 -6.69 -5.94 -4.09 -1.94 -1.91 3.71 3.11 0.93
Invested Capital Turnover
-109.17 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital
-0.92 -1.15 -3.68 -6.19 -5.03 -2.94 1.75 4.79 9.66 7.20 2.87
Enterprise Value (EV)
185 234 150 173 -10 -73 147 1.13 241 376 260
Market Capitalization
110 453 364 378 181 103 329 264 488 613 505
Book Value per Share
($31.92) $8.46 $11.07 $7.68 $7.14 $6.62 $6.44 $11.30 $6.70 $6.41 $6.52
Tangible Book Value per Share
($31.92) $8.46 $11.07 $7.68 $7.14 $6.62 $6.44 $11.30 $6.70 $6.41 $6.52
Total Capital
117 218 210 198 185 171 180 261 250 240 245
Total Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt
-118 -219 -214 -205 -191 -175 -182 -263 -246 -237 -244
Capital Expenditures (CapEx)
0.15 0.12 0.08 0.17 0.05 0.04 0.10 0.04 0.31 0.01 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-4.43 -2.07 -4.57 -8.35 -7.53 -5.86 -3.84 -4.72 -0.02 -0.50 -2.77
Debt-free Net Working Capital (DFNWC)
113 217 209 196 183 170 179 258 246 236 242
Net Working Capital (NWC)
113 217 209 196 183 170 179 258 246 236 242
Net Nonoperating Expense (NNE)
1.47 1.35 1.19 2.63 3.31 3.51 2.34 3.18 2.62 2.95 4.02
Net Nonoperating Obligations (NNO)
-118 -219 -214 -205 -191 -175 -182 -263 -246 -237 -244
Total Depreciation and Amortization (D&A)
-0.96 -1.01 -0.72 0.08 -0.21 -0.33 0.09 -0.02 -0.31 -0.72 0.75
Debt-free, Cash-free Net Working Capital to Revenue
-8.86% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue
226.95% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue
226.95% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
($3.55) ($0.39) ($0.40) $2.16 ($0.62) ($0.62) ($0.45) ($0.48) ($0.39) ($0.40) ($0.49)
Adjusted Weighted Average Basic Shares Outstanding
2.37M 23.36M 25.73M 19.35M 25.87M 25.90M 28.12M 27.70M 37.34M 37.47M 38.39M
Adjusted Diluted Earnings per Share
$0.00 ($0.39) ($0.40) $0.00 $0.00 $0.00 $0.00 $0.00 ($0.39) ($0.40) ($0.49)
Adjusted Weighted Average Diluted Shares Outstanding
25.72M 23.36M 25.73M 19.35M 25.87M 28.04M 23.10M 27.70M 37.34M 37.47M 38.39M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
25.72M 18.99M 25.78M 25.87M 25.87M 28.04M 23.10M 37.34M 37.39M 37.62M 39.27M
Normalized Net Operating Profit after Tax (NOPAT)
-6.95 -7.66 -9.08 -12 -13 -13 -10 -12 -12 -12 -15
Normalized NOPAT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
2.67% 0.00% 0.00% 0.00% 0.28% -0.31% -0.43% -0.43% -0.56% -0.35% -0.09%

Financials Breakdown Chart

Key Financial Trends

Contineum Therapeutics remains a development-stage biotechnology company with no reported revenue in the periods provided. Its financial profile is defined by recurring research spending, operating losses and reliance on cash and investments to fund clinical development.

Liquidity remains the company’s main financial strength. As of June 30, 2026, Contineum held $14.7 million in cash and equivalents plus $221.8 million in short-term investments, or approximately $236.0 million in highly liquid assets. Total liabilities were only $10.7 million, while the current ratio was approximately 37.2 times. This provides a substantial cushion relative to near-term obligations.

  • Large liquidity position: Cash and short-term investments totaled approximately $236.0 million at the end of Q2 2026, supporting continued investment in the pipeline.
  • Low leverage: Total liabilities of $10.7 million represented only about 4% of total assets, meaning the company is not heavily dependent on debt financing.
  • Operating cash burn improved sequentially: Cash used in operating activities declined from $16.3 million in Q1 2026 to $11.5 million in Q2 2026.
  • Research spending remains substantial: Q2 2026 research and development expense was $12.7 million, indicating that the company continues to prioritize advancing its drug candidates.
  • Interest income provides partial support: Interest and investment income was $2.3 million in Q2 2026, helping offset a portion of operating expenses while the company holds significant short-term investments.
  • Potential cash runway appears meaningful: Using Q2’s $11.5 million quarterly operating cash burn as a simple reference, the company’s liquid assets could support several years of operations. Actual runway will depend on clinical spending, acquisitions, capital raises and changes in investment income.
  • Investment activity largely reflects portfolio management: Contineum purchased $45.8 million of investments and received $50.6 million from investment sales or maturities in Q2 2026, producing $4.9 million of investing cash flow. These transactions do not represent operating revenue.
  • No commercial revenue: Revenue has been reported at zero across the recent quarters, leaving the company dependent on its balance sheet and future financing until a product is successfully commercialized.
  • Losses remain persistent: Contineum reported a net loss of $15.2 million in Q2 2026, following losses of $14.5 million in Q1 2026, $15.2 million in Q4 2025 and $12.8 million in Q3 2025.
  • Operating expenses are elevated and generally rising over the longer term: Q2 2026 operating expenses totaled $17.4 million, compared with $10.9 million in Q2 2024. Research and development spending is the largest component, while Q2 selling, general and administrative expense increased to $4.7 million.

The balance sheet has weakened modestly during 2026. Total assets declined from $261.3 million at March 31 to $250.4 million at June 30, while cash and short-term investments fell by approximately $10.4 million. Retained earnings also declined to a deficit of $207.0 million, reflecting the company’s accumulated losses.

Shareholder dilution is another issue for investors to monitor. Weighted average basic shares outstanding increased from 27.7 million in Q4 2025 to 37.5 million in Q2 2026. The company also reported $93.4 million of common-equity issuance in Q4 2025. While equity financing has strengthened the balance sheet, additional share issuance can reduce existing investors’ ownership percentages and may pressure per-share results.

Overall, Contineum’s financial statements show a well-funded but unprofitable biotechnology company. Its strong liquidity and minimal liabilities reduce near-term financing risk, but the company continues to consume cash, generate no revenue and depend on successful clinical development before it can become self-sustaining.

11/17/26 06:43 PM ETAI Generated. May Contain Errors.

Contineum Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Contineum Therapeutics' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Contineum Therapeutics' net income appears to be on a downward trend, with a most recent value of -$59.98 million in 2025, compared with $22.72 million in 2023. The previous period was -$42.26 million in 2024. See Contineum Therapeutics' forecast for analyst expectations on what's next for the company.

Contineum Therapeutics' total operating income in 2025 was -$68.06 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $68.06 million

Over the last 2 years, Contineum Therapeutics' total revenue changed from $50 million in 2023 to $0.00 in 2025, a change of -100.0%.

In the past 10 quarters, Contineum Therapeutics' cash and equivalents has ranged from $14.71 million in Q2 2026 to $77.23 million in Q2 2024, and is currently $75.20 million as of their latest financial filing in Q3 2026.

Contineum Therapeutics had total debt of $0.00 at the end of 2025, compared with none in 2024, and none in 2023.

Over the last 2 years, Contineum Therapeutics' book value per share changed from -29.42 in 2023 to 11.30 in 2025.



Financial statements for NASDAQ:CTNM last updated on 11/3/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners